← Eichor
Condition: Melanoma Uveal Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Melanoma Uveal

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant Tebentafusp for Uveal Melanoma
Phase 2 · 2 location(s) · Thomas Jefferson University · NCT06414590
Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Phase 1 · 1 location(s) · Inge Marie Svane · NCT07501117
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT06961357
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Phase 2 · 1 location(s) · University of Miami · NCT06627244
Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
Phase 1 · 2 location(s) · St Vincent's Hospital, Sydney · NCT07203391
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatm
Phase 3 · 71 location(s) · Aura Biosciences · NCT06007690
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Phase 3 · 94 location(s) · IDEAYA Biosciences · NCT07015190
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiat
Phase 1 · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT05607095
Adjuvant Quisinostat in High-Risk Uveal Melanoma
Phase 2 · 1 location(s) · University of Miami · NCT06932757
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Phase 2 · 3 location(s) · Diwakar Davar · NCT06070012
Observational Study of Iris Tumors
Phase N/A · 1 location(s) · Oregon Health and Science University · NCT03809585
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Phase 1/Phase 2 · 21 location(s) · Immatics US, Inc. · NCT03686124
Retrospective Register for Uveal Melanoma
Phase N/A · 1 location(s) · Medical University of Vienna · NCT05733728
PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases
Phase 3 · 6 location(s) · Vastra Gotaland Region · NCT06519266
Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Phase N/A · 1 location(s) · Hadassah Medical Organization · NCT01438658
Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
NA · 1 location(s) · Institut Curie · NCT04424719
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Phase 1 · 5 location(s) · MonTa Biosciences ApS · NCT04855435
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients
Phase 1 · 16 location(s) · OncoNano Medicine, Inc. · NCT06022029
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Mela
Phase 1 · 4 location(s) · Alpha-9 Oncology USA Inc. · NCT07076550
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Phase 2 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT07276386
Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
Phase 2 · 4 location(s) · Grupo Español Multidisciplinar de Melanoma · NCT07057596
Adjuvant Tebentafusp in High Risk Ocular Melanoma
Phase 3 · 15 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06246149
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Phase 1/Phase 2 · 15 location(s) · IDEAYA Biosciences · NCT03947385
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Phase N/A · 1 location(s) · Mohamed Abdel-Rahman · NCT04792463
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
NA · 1 location(s) · Massachusetts General Hospital · NCT07364474
MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
Phase 1/Phase 2 · 1 location(s) · Erasmus Medical Center · NCT04729543
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Phase 1/Phase 2 · 5 location(s) · Iovance Biotherapeutics, Inc. · NCT06940739
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
Phase 1/Phase 2 · 3 location(s) · Novelwise Pharmaceutical Corporation · NCT07136181
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.